RISK WATCHYahoo Finance • 10h ago
Alnylam Pharmaceuticals (ALNY) Stock Looks Fully Priced Following Its 52% FallYahoo Finance report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
Why ALNY Stock dropped -5.17% Today — RQD Quant Desk Flash
$165.00 -5.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $163.15
Alnylam Pharmaceuticals Inc. (ALNY) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $23.28B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ALNY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ALNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $165.00 (-5.17% 1D, market cap $23.28B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ALNY ranks #223 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ALNY compare to INSM and VTRS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALNY carries a Roarable D+ (55/100 RQD), trailing P/E of 74.2x, gross margin of 81.8%, and ROIC of 21.3%. By comparison, INSM (Insmed Incorporated) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.37B) and VTRS (Viatris Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC -8.1%, cap $22.05B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ALNY?
▼
Per ALNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001178670), Alnylam Pharmaceuticals Inc. generated $3.71B in revenue (+65.2% YoY), $313.7M in net income, and $465.4M in free cash flow against $4.97B in total assets and $1.88B in total debt. Key quantitative strengths: Strong cash generator (82% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $163.15 (-1.12%)🧬 Disciplined Float (-0.04% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 12.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-1.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALNY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY ALNY SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (31% of score)
SEC XBRL FY 2025 (10-K): 12.5% FCF Margin ($465.4M FCF) & 81.8% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)
Altman Z-Score 3.16 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)
Macro rate sensitivity & RSI-14 (28.2) create a -15 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$223.82+3.1% Next Q
63
Q2 (-2Q)Grade C$230.71-1.7% Next Q
60
Q3 (-1Q)Grade C$226.79-27.2% Next Q
58
CurrentGrade D+$165.00-0.5% Hist 90D α
55
Trajectory: C+ (63) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the ALNY Bull Thesis Could Fail
Even with a 55/100 (D+) score, ALNY faces multiple-compression risk if 74.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Priced at 74x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($234.01) or 200D SMA ($283.63) invalidates the momentum regime and cuts Target Base ($162.77) toward Bear Floor ($126.96).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALNY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALNY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ALNY Stock dropped -5.17% Today — RQD Quant Desk Flash
Alnylam Pharmaceuticals Inc. (ALNY) dropped -5.17% to $165.00, trading at 2% of its 52-week range ($163.3 – $479.79). Stretched risk/reward at 74x P/E (21% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($163.3 – $479.79) with RSI-14 at 28.2 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $165.00 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 81.8% gross margin and $465.4M annual free cash flow.
Live ALNY Headlines & Catalysts
MARKET WIRETrefis • 13h ago
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14%Trefis report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
CATALYSTChartMill • 16h ago
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and GrowthChartMill report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 19h ago
Alnylam vs. Ionis: Here's the Better Bad-News BuyThe Motley Fool report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 22h ago
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?Yahoo Finance report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 1d ago
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?The Motley Fool report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETrefis • 1d ago
Should You Buy The Dip In Alnylam Stock?Trefis report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Alnylam Pharmaceuticals (ALNY) Looks Undervalued On Paper, Can Its RNAi Pipeline Support Fair Value?Yahoo Finance report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 12h ago
Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and MorePre-Market Stock Futures: Futures are trading higher after a rough week in which sellers moved hard against the big tech companies, which reported mostly solid results. Still, massive spending on AI, free cash flow that
MARKET WIREYahoo • 14h ago
FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In SpotlightNovember brings several closely watched FDA decisions, with Regeneron and its partner Alnylam’s therapy for generalized myasthenia gravis and Roche’s Gazyva for primary membranous nephropathy in the spotlight this week.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALNY)
- ✓Walkthrough of ALNY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ALNY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.62%🛡️ HOLDING TREND SUPPORT
2026-11-02O $232.4H $232.4L $165.0C $165.0VOL 11.80M
RES: $245.6SUP: $162.2SMA50: $234.0SMA200: $283.6
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ALNY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
47.6%/yr Implied 5Y Growth
vs. +65.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ALNY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ALNY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALNY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALNY)
Health Care Rank #223 of 1016
⚔️ INSM vs ALNY Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ALNY vs. INSM, VTRS, UTHR, ROIV)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Alnylam Pharmaceuticals Inc. (ALNY) ranks #223 by composite RQD confidence (55/100, grade D+) and #67 by equity capitalization ($23.28B). Within this direct 5-issuer industry benchmark cohort, UTHR leads on earnings valuation at 19.1x trailing P/E, while ALNY leads on capital efficiency and profitability with 21.3% ROIC and 81.8% gross margin. UTHR currently holds the highest overall quantitative score in the immediate peer group at 82/100 (A-) compared with ALNY at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALNY
ACTIVE
Alnylam Pharmaceuticals Inc. | D+ | 55/100 | 74.2x | 81.8% | 21.3% | -5.17% | $23.28B | Benchmark Subject |
| INSM Insmed Incorporated | D | 44/100 | — | 79.7% | -35.0% | +0.89% | $24.37B | /insm-vs-alny → |
| VTRS Viatris Inc. | D+ | 57/100 | — | 35.2% | -8.1% | -0.86% | $22.05B | /vtrs-vs-alny → |
| UTHR United Therapeutics Corporation | A- | 82/100 | 19.1x | 87.9% | 20.1% | +0.87% | $25.46B | /uthr-vs-alny → |
| ROIV Roivant Sciences Ltd. | D | 44/100 | — | — | -14.0% | -1.63% | $27.10B | /roiv-vs-alny → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001178670In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alnylam Pharmaceuticals Inc. (ALNY) reported GAAP revenue of $3.71B (+65.2% vs. FY2024 revenue of $2.25B , and +103.1% cumulative change since FY2023) , GAAP net income of $313.7M, operating cash flow of $524.1M, and free cash flow of $465.4M (+1192.7% YoY). On the balance sheet, ALNY closed FY2025 with $4.97B in total assets against $1.88B in total debt (Altman Z-Score: 3.16, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.71B | $313.7M | $524.1M | $465.4M | $4.97B | $1.88B |
| FY2024 (FY) | 2024-12-31 | $2.25B | -$278.2M | -$8.3M | -$42.6M | $4.24B | $1.88B |
| FY2023 (FY) | 2023-12-31 | $1.83B | -$440.2M | $104.2M | $21.9M | $12.81B | $3.00B |
3. ALNY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ALNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $165.00 (-5.17% 1D, market cap $23.28B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ALNY ranks #223 in composite RQD confidence.
How does ALNY compare to INSM and VTRS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALNY carries a Roarable D+ (55/100 RQD), trailing P/E of 74.2x, gross margin of 81.8%, and ROIC of 21.3%. By comparison, INSM (Insmed Incorporated) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.37B) and VTRS (Viatris Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC -8.1%, cap $22.05B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ALNY?
Per ALNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001178670), Alnylam Pharmaceuticals Inc. generated $3.71B in revenue (+65.2% YoY), $313.7M in net income, and $465.4M in free cash flow against $4.97B in total assets and $1.88B in total debt. Key quantitative strengths: Strong cash generator (82% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ALNY trading relative to its 50-day, 200-day, and 52-week technical levels?
ALNY last traded at $165.00 (-5.17% on volume of 7,056,830 shares), positioning the stock -29.49% below its 50-day simple moving average ($234.01) and -41.83% below its 200-day simple moving average ($283.63). Across its 52-week range of $163.30 to $479.79, ALNY sits at the 0.5% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($144.37 to $185.63).
ALNY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ALNY stock moving today?
Why ALNY Stock dropped -5.17% Today — RQD Quant Desk Flash. Stretched risk/reward at 74x P/E (21% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 55/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ALNY — Alnylam Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:13:08Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating is 55, graded D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." Per the Roarable RQD rating, the five pillars score as follows:
- Fundamental Cash Engine: 17 / 20. Supported by ROIC of 21.3% and a free cash flow yield of 2%. This is the strongest pillar and indicates that the business generates returns on invested capital, though the low FCF yield means investors are paying a high price relative to current cash generation.
- Whale 13F Flow: 7 / 20. Reflects institutional accumulation and options positioning. A low score here suggests limited evidence of strong institutional conviction in the source data.
- Insider Conviction: 12 / 20. Reflects SEC Form 4 and Congressional PTR cluster flow. A mid-range score indicates neither a clear insider buying signal nor a strong selling signal in the source data.
- Macro Regime Fit: 5 / 20. Reflects beta of 1 and sector sensitivity. This is the weakest pillar and suggests limited alignment between the stock's profile and the current macro backdrop as captured by this rating.
- Forensic Balance Sheet: 14 / 20. Supported by Altman Z of 3.16, Piotroski F of 8/9, and Debt/Equity of 2.22. The Altman and Piotroski readings are constructive, while the elevated leverage ratio is a counterweight.
For a prospective investor, the rating points to a profile where operating economics and balance-sheet metrics are comparatively better than market-facing signals. The price has declined 25.13% per the market data, with a 52-week range of $163.3 – $479.79. Valuation metrics are elevated per the market data: P/E (TTM) of 74.2, forward P/E of 62.3, and EV/EBITDA of 42.4. Those multiples imply that much of the future growth is already priced in, so the upside case depends on sustained earnings expansion, while the downside case is exposed to any slowdown. The rating's verdict is a Sell/Trim classification and should be read as the framework's assessment, not as personalized advice.
Snapshot
Business
Alnylam Pharmaceuticals Inc. is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the profile. Per the market data, the company reports an 81.8% gross margin, indicating high product-level economics. Source data does not specify its products, customers, or specific revenue model beyond the sector and industry classification.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $3713.9M | $501.6M | $313.7M | N/A | $465.4M | $1657.2M | $1879.7M |
| FY 2024 | $2248.2M | $-176.9M | $-278.2M | N/A | $-42.6M | $966.4M | $1877.8M |
| FY 2023 | $1828.3M | $-282.2M | $-440.2M | N/A | $21.9M | N/A | $2996.5M |
Per the SEC financials, reported revenue grew from $1828.3M (FY 2023) to $3713.9M (FY 2025), with operating income turning positive in FY 2025 at $501.6M. Per the market data, the operating margin is 13.5% and net margin is 8.4%, with ROIC of 21.3%. Per the Roarable RQD rating, the forensic balance sheet shows an Altman Z-Score of 3.16, a Piotroski F-Score of 8/9, and Debt/Equity of 2.22. Debt was $1879.7M against cash of $1657.2M in FY 2025 per the SEC financials.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts section, the feed contains six items, all tagged to ALNY:
- RISK WATCH (RED): A Yahoo Finance item headlined that the stock "Looks Fully Priced Following Its 52% Fall."
- MARKET WIRE (YELLOW): A Trefis item noting five straight red trading days with the stock down 14%.
- CATALYST (GREEN): A ChartMill item framing the company as a decent value stock balancing undervaluation and growth.
- MARKET WIRE (YELLOW): A Motley Fool comparison of Alnylam and Ionis as a "better bad-news buy."
- MARKET WIRE (YELLOW): A Yahoo Finance item asking whether the RNAi franchise could earn an S&P 500 index entry.
- MARKET WIRE (YELLOW): A Motley Fool item questioning why investors treat a solidly profitable company like a broken biotech.
Per the butterfly supply-chain graph, the supply chain is marked "NONE," with no butterfly links and no proprietary signals.
Open Questions
- What are the company's specific revenue drivers and product lines behind the FY 2025 revenue increase to $3713.9M?
- Why is EPS reported as N/A across all periods, and what is the basis for the EPS (TTM) of 2.34?
- What is the composition of the $1879.7M debt, including maturity profile and interest burden?
- Who are the institutional holders and insiders, and what are their recent position changes?
- What analyst consensus, rating, or price targets exist for the stock?
ALNY Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Alnylam Pharmaceuticals Inc. (ALNY) • Click "Debate This Headline" to argue it in the Roar Pit below
🔴 RISK WATCH Yahoo Finance • 10h ago
Alnylam Pharmaceuticals (ALNY) Stock Looks Fully Priced Following Its 52% Fall Yahoo Finance report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 13h ago
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% Trefis report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ChartMill • 16h ago
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth ChartMill report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 19h ago
Alnylam vs. Ionis: Here's the Better Bad-News Buy The Motley Fool report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 22h ago
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index? Yahoo Finance report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 1d ago
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? The Motley Fool report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 1d ago
Should You Buy The Dip In Alnylam Stock? Trefis report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Alnylam Pharmaceuticals (ALNY) Looks Undervalued On Paper, Can Its RNAi Pipeline Support Fair Value? Yahoo Finance report covering Alnylam Pharmaceuticals Inc. (ALNY) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ALNY Bull vs. Bear Conversation Board — What's Your Call at $165.00?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALNY 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $187.92 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ALNY (D+ • RQD 55/100) a Buy at $174.00?
Welcome to the ALNY (Alnylam Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (21.3% ROIC), while bears focus on valuation multiple compression (74.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $135.72 (-22.0%)
Spot @ $174.00 Pump the brakes on ALNY — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ALNY, but look at what you are paying: 74.2x trailing P/E with 81.8% gross margins. Unless Alnylam Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $208.80 (+20.0%)
Spot @ $174.00 ALNY cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ALNY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $174.00 (52-wk range $163.30 - $479.79), any beat on forward guidance forces shorts and underweight funds to chase.